Sectra AB (SECT-B) Fair Value & Analysis
Healthcare · SE · Market cap 53.0B SEK (≈ $5.5B) · ISIN SE0022419784
What is Sectra AB really worth?
A solid business, but trading 335% above our fair value of kr 66.81.
Strengths
Risks
For context
Fair value as of: Aug 13, 2026
From 24 valuation models · updated 22 days ago
Share price +8.4% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- A high-quality business (quality 72/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- The price sits above even our optimistic bull case (kr 81.10). The favourable scenario is already priced in.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range kr 107.56 – kr 370.75 · fair‑value band kr 51.81 – kr 81.10 · the kr 290.40 price screens above the kr 66.81 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Sectra AB (SECT-B) currently trades at kr 290.40, while our model-based Fair Value estimate is kr 66.81, implying the stock looks roughly 334.6% overvalued today. The Quality Score stands at 72/100 (solid quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of kr 90.75 per share, and 0 of the 24 models we run sit above the kr 290.40 price. Bear case: the Asset-Based group reads lowest at kr 7.98, and 24 of the 24 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, Sectra AB generated revenue of 3.6B SEK at a net margin of 15.5%. Revenue grew 13.0% year over year. It earns a return on equity of 27.8%. The balance sheet holds a net cash position of 1.7B SEK. Fundamentals as of Aug 13, 2026
Our scenario range runs from kr 51.81 (bear case) to kr 81.10 (bull case); at kr 290.40, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 23% below its 52-week high and 68% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −34% fair-value upside, at −77%, SECT-B screens richer than that median.
Fair Value models
This estimate rests on fiscal year 2026 figures, and about 4 months have passed since. In that time the company retained roughly kr 0.5672 per share, which is 0.8 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 24 models by family
Widest divergence: DCF Models (kr 90.75) versus Asset-Based (kr 7.98). Highest evidence: FCF DCF (78).
Notify me when SECT-B reaches fair value
Put SECT-B on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 73 · Market factors (momentum, volatility) 53
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Sectra AB (publ) provides solutions for medical IT and cybersecurity sectors in Sweden, the United Kingdom, the Netherlands, and rest of Europe. The company operates through Imaging IT Solutions, Secure Communications, and Business Innovation segments.
Full company description
Sectra AB (publ) provides solutions for medical IT and cybersecurity sectors in Sweden, the United Kingdom, the Netherlands, and rest of Europe. The company operates through Imaging IT Solutions, Secure Communications, and Business Innovation segments. The Imaging IT Solutions segment develops and sells medical IT systems and services for managing, archiving, and presenting various types of medical images and patient information, as well as for operational follow-up and radiation dose monitoring; and maintenance and consulting services. The Secure Communications segment develops and sells products and services for secure voice and data communications, and project-based development, as well as security and threat analyses, and system monitoring services for control systems. The Business Innovation segment develops and sells IT systems for planning and monitoring orthopedic surgery; products for medical education and research projects; and IT support services for precision diagnostics in cancer care. It serves hospitals and private clinic chains. Sectra AB (publ) was incorporated in 1957 and is headquartered in Linköping, Sweden.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Sectra AB reported revenue of 3.5B SEK in FY2026 versus 1.9B SEK in FY2022, a compound +16.1%/yr. Reported net income was 564M SEK in FY2026, compounding +15.7%/yr from FY2022.
of which total revenue +13.3 % · buybacks/dilution −0.1 %
Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).
SECT-B screens 335% overvalued. Compare with Abbott Laboratories, →
Recent news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- Invitation to presentation of Sectra's three-month report 2026/2027
- Loyalist College advances medical imaging training with Sectra's Education Portal
- Hennick Humber Hospital in Canada has selected Sectra One Cloud to speed up patient diagnostics with improved radiology workflows
- Sectra achieves the highest level of security attestation for healthcare providers adopting cloud services in Germany
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $112.47 | $74.79 | −34% |
| Stryker Corporation SYK | $322.12 | $186.28 | −42% |
| Medtronic plc MDT | $89.97 | $65.57 | −27% |
| Boston Scientific Corporation BSX | $46.84 | $30.73 | −34% |
| Edwards Lifesciences Corporation EW | $89.78 | $41.02 | −54% |
| Siemens Healthineers AG SHL | €39.52 | €33.87 | −14% |
| DexCom, Inc DXCM | $90.82 | $38.95 | −57% |
| GE HealthCare Technologies Inc GEHC | $74.82 | $64.13 | −14% |
| Koninklijke Philips N.V PHIA | €23.69 | €14.36 | −39% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥150.63 | ¥147.63 | −2% |
Compare Sectra AB with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Sectra AB (SECT-B) overvalued or undervalued?
What is the fair value of SECT-B?
What is the quality score of SECT-B?
What is the revenue of Sectra AB (SECT-B)?
What is the net profit margin of SECT-B?
Does Sectra AB pay a dividend?
Watch Sectra AB in the live analysis
One click puts Sectra AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.